DNLI

Denali Therapeutics Inc. discovers, develops, and delivers biotherapeutics aimed at treating serious diseases, particularly those affecting the brain and body. The company utilizes its proprietary TransportVehicle™ platform to create barrier-crossing therapeutics, focusing on neurodegenerative diseases and lysosomal storage disorders. Denali's pipeline includes a range of investigational therapies designed to address these conditions, with an emphasis on collaboration with the patient community to inform its research and development efforts.